Certificate course in Cardiovascular Pharmacology

Explore how blood pressure arises from cardiac output and peripheral resistance, by heart rate, stroke volume, arteriolar diameter, and autonomic factors, including sympathetic signaling and adrenergic receptors, guiding antihypertensive classification.

Diuretics form a key antihypertensive group, lowering blood volume and sodium. Thiazides serve as first-line; indapamide works at low doses with fewer metabolic effects; loop diuretics suit severe cases.

Explore sympathoplegics that reduce sympathetic nervous system activity to prevent hypertension by diminishing central outflow, blocking autonomic ganglia, depleting neurotransmitters, and inhibiting adrenergic receptors.

Explain how alpha-2 agonists and beta-1 antagonists reduce central sympathetic outflow to treat hypertension, highlighting clonidine, alpha-methyldopa, and newer imidazoline receptor drugs like moxonidine and rilmenidine.

Ganglion blockers inhibit nicotinic nn receptors in ganglia, lowering blood pressure by reducing sympathetic transmission, with dry mouth and urinary retention as adverse effects; examples include hexamethonium, trimethoprim, and mecamylamine.

Adrenergic neuron blockers deplete sympathetic neurotransmitters, with reserpine inhibiting vesicular uptake of adrenaline, dopamine, and serotonin causing depression, while guanethidine and bretylium displace norepinephrine, lowering neurotransmission and causing postural hypotension.

Block alpha one receptors with selective or non-selective adrenergic antagonists to cause vasodilation and lower blood pressure, aiding hypertension management and benign prostatic hyperplasia, including pheochromocytoma crises.

Beta blockers block beta-1 receptors to reduce cardiac output, renin release, central sympathetic outflow, and raise cyclin levels to promote vasodilation, especially with cardioselective beta-1 blockers in hypertension with diabetes.

Explains selective beta-1 blockers and bradycardia risk, intrinsic sympathomimetic activity drugs, and combined alpha and beta blockers like labetalol and carvedilol for pheochromocytoma and heart failure.

Learn how vasodilators lower blood pressure by arterial, venous, or mixed dilation through potassium channel opening, nitric oxide release, calcium channel blockade, or dopamine receptor agonism.

Open potassium channels in arterioles with hydralazine, minoxidil, and diazoxide to cause arteriolar vasodilation, with hydralazine releasing nitric oxide from intact endothelium and minoxidil acting as a liver-activated prodrug.

Nitric oxide releasing vasodilators, including sodium nitroprusside and hydralazine, promote vasodilation. Sodium nitroprusside is short acting and IV for hypertensive emergencies; prolonged use risks cyanide toxicity and hypothyroidism.

Dopamine agonists activate D2 receptors and are used as monotherapy in parkinsonism; ergot bromocriptine and pergolide carry vascular and fibrotic risks, while non ergot pramipexole and ropinirole are long acting.

Calcium channel blockers, especially dihydropyridines, mainly vasodilate by blocking L-type channels in vessels; verapamil and diltiazem depress cardiac activity, with verapamil stronger than diltiazem.

Calcium channel blockers cause vasodilatation and reflex tachycardia; long-acting nicardipine is the drug of choice for hypertensive emergencies, while sustained-release nifedipine or amlodipine reduce reflex tachycardia.

Nimodipine is a cerebral selective vasodilator reversing vasoconstriction after subarachnoid hemorrhage. Clevidipine is an ultra short-acting dihydropyridine for hypertensive emergencies.

renin inhibitors directly inhibit renin, blocking angiotensinogen to angiotensin I conversion and lowering blood pressure; drugs like aliskiren and remikiren are taken orally for chronic hypertension.

Explore how ACE inhibitors block angiotensin I to II conversion, raise bradykinin, and reduce proteinuria, with drug profiles, uses, and key adverse effects.

Angiotensin receptor blockers (losartan, valsartan, irbesartan, candesartan, telmisartan, eprosartan) antagonize angiotensin II at AT1 receptors, do not raise bradykinin, reducing cough and angioedema, and inhibiting the distal Ras pathway.

We outline safe antihypertensives for pregnancy using the better mother care mnemonic: beta blockers (cardioselective and labetalol), methyldopa, clonidine, dihydropyridine calcium channel blockers, hydralazine, and prazosin.

Explore hypertension with coexisting conditions and the corresponding drug choices, including beta blockers, calcium channel blockers, ACE inhibitors, ARBs, diuretics, and alpha blockers.

Explore how myocardial ischemia from obstructed, vasospastic, or microvascular coronary flow causes angina pectoris, and how anti-anginal drugs target heart rate, blood pressure, and myocardial oxygen demand.

Classify antianginal drugs into nitrates, calcium channel blockers, beta blockers, potassium channel openers, fatty acid oxidation inhibitors, and sodium channel blockers, and discuss their mechanisms and clinical use.

Explore nitrates as antianginals, detailing the nitric oxide–cGMP mechanism, venous-dominant dilation that reduces preload, ischemic blood flow redistribution, and dipyridamole’s coronary steal phenomenon.

Describe nitrate administration routes—sublingual for acute angina relief, oral or transdermal for prophylaxis; note duration, first-pass metabolism, and cyanide toxicity via methemoglobin.

Explain major adverse effects of nitrates, including tachycardia, flushing, and headache. Discuss tolerance by route, eight-hour drug-free periods, and the risk of profound hypotension with phosphodiesterase inhibitors such as sildenafil.

Identify calcium channel blockers used for angina, including verapamil, diltiazem, and long-acting dihydropyridines; avoid short-acting nifedipine due to tachycardia, while noting mechanism and key adverse effects.

Beta blockers reduce cardiac workload by blocking beta1 receptors in the heart, do not dilate coronary vessels, and may cause coronary vasoconstriction, so they are contraindicated in variant angina.

Trimetazidine inhibits fatty acid oxidation, boosts glucose use, and reduces lipid peroxidation to protect the myocardium in angina. Ranolazine blocks late sodium current, first-line for chronic angina with QT risk.

Ivabradine lowers heart rate by blocking the funny current channel, reducing energy demand in angina; Fasudil inhibits Rho kinase to cause vasodilation and lower afterload.

Explore the three angina types: stable angina from coronary atherosclerosis, unstable angina from plaque rupture with platelet aggregation and coagulation, and Prinzmetal angina from coronary vasospasm.

Explore stable angina, caused by narrowing of the coronary arteries, and its management with sublingual nitrates for acute attacks and long-term prevention using beta blockers, calcium channel blockers, and antiplatelets.

Explain unstable angina pathogenesis from plaque rupture to platelet aggregation and coagulation activation, and cover acute coronary syndrome classification and pharmacologic management with nitrates, beta blockers, antiplatelets, anticoagulants, and statins.

Variant angina arises from coronary vasospasm that acutely reduces blood flow. Use sublingual nitrate for acute attacks; dihydropyridines and nitrates for prophylaxis; avoid aspirin and beta blockers, which worsen vasospasm.

Examine antianginal drugs including nitrates, beta blockers, calcium channel blockers, ranolazine, and ivabradine, detailing nitric oxide–mediated preload reduction, late sodium and funny current mechanisms, and exam-style mcq insights.

Classify heart failure into preserved and reduced ejection fraction based on contractile function, explaining diastolic heart failure (preserved EF) and systolic heart failure (reduced EF).

Explore etiologies of heart failure with reduced ejection fraction, defined by ejection fraction under 40%, including coronary artery disease, chronic pressure/volume overload, dilated cardiomyopathy, and viral or Chagas infections.

Explore heart failure with preserved ejection fraction, a diastolic heart failure with normal ejection fraction. Identify etiologies such as hypertrophic and restrictive cardiomyopathy, aging, and cor pulmonale from pulmonary disease.

Classify right ventricular failure into acute and chronic, linking acute cases to massive pulmonary embolism and chronic cases to COPD, through increased afterload on the right ventricle.

Explain how right ventricular failure raises jugular venous pressure, causes tender hepatomegaly and pedal edema, and yields portal hypertension with ascites, intestinal edema, and a right ventricular third heart sound.

Explain the left heart failure clinical features, including reduced cardiac output and pulmonary congestion with dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Note basal crepitations, oliguria, and S3 signs.

Assess heart failure through chest x ray, BNP and NT Probnp levels, and two dimensional echocardiography to evaluate ejection fraction. Include electrocardiography and labs to identify etiology and prognosis.

Master congestive heart failure management through lifestyle changes and drugs, including diuretics, inotropes, and beta blockers, plus ACE inhibitors or ARBs and aldosterone antagonists to relieve symptoms and improve survival.

Assess fluid retention in heart failure; use diuretics if present, otherwise start ACE inhibitors and beta blockers in NYHA classes, then add aldosterone antagonists, nitrates, or digoxin if symptoms persist.

Use vasopressin antagonists, such as tolvaptan (oral) and conivaptan (intravenous), to neutralize vasopressin, reduce afterload and water reabsorption, and correct dilutional hyponatremia in congestive heart failure.

Examine anticoagulation in heart failure for thromboembolism risk (atrial fibrillation, valvular disease, low ejection fraction) with heparins, vitamin K antagonists, DOACs, and omega-3s for NY class two to four.

Explore nonpharmacological heart failure treatments, including biventricular pacing (cardiac resynchronization therapy) and implantable cardioverter defibrillator (ICD), and surgical options like left ventricular aneurysmectomy, left ventricular assist devices, and cardiac transplantation.

Learn to manage chronic heart failure across NY functional classes I, II, III, IV with lifestyle and sodium restrictions, and apply drugs like ACE inhibitors, beta blockers, diuretics, and spironolactone.

Identify and manage precipitating factors, including infections, anemia, pregnancy, thyrotoxicosis, arrhythmias, myocarditis, myocardial infarction, accelerated hypertension, pulmonary embolism, drugs such as beta blockers, disopyramide, corticosteroids, NSAIDs, salt, stress, and noncompliance.

Reduce cardiac remodeling with ACE inhibitors, ARBs, and aldosterone antagonists; lower cardiac workload with beta blockers, vasodilators, diuretics, and lifestyle changes.

Arrhythmia means deviation from the normal cardiac rhythm of 60–100 bpm and prompts discussion of antiarrhythmic drugs. Understand automaticity in the SA node and conduction through AV and Purkinje pathways.

Explore how the cardiac action potential varies across the SA node, AV node, and ventricular muscle, highlighting automaticity, pacemaker activity, resting membrane potential, and potassium’s role.

Explore phase zero of the cardiac action potential, including Vmax and fast sodium channel states, and how resting membrane potential shapes excitability and arrhythmia risk.

Explore phase one inactivation of fast sodium channels and downward deflection from potassium and chloride, phase two plateau from calcium–potassium balance, and phase three repolarization; relate to ECG.

Explain the Singh and Vaughan Williams five-class antiarrhythmic classification, with emphasis on class I sodium channel blockers, their use-dependent blockade, and subclassification into 1A, 1B, and 1C.

Class i a antiarrhythmics block sodium and potassium channels, delay repolarization, and prolong action potential duration, leading to torsades de pointes; examples include quinidine, procainamide, disopyramide.

Quinidine, a class one agent derived from the cinchona plant, has anti-malarial action poorer than quinine. It can cause nausea, vomiting, diarrhea, hypotension, and hypoglycemia.

Procainamide, an orally active procaine derivative and class 1A antiarrhythmic, undergoes hepatic acetylation to N-acetyl procainamide, which blocks potassium channels and treats supraventricular and ventricular arrhythmias, including ventricular premature beats.

Class one B antiarrhythmic agents include lignocaine, mexiletine, tokenide, and phenytoin, are sodium channel blockers with potassium channel opening, causing fast onset and reduced refractoriness for ventricular arrhythmias.

Class I C antiarrhythmics are most potent sodium channel blockers with negligible potassium channel effects and slow kinetics, used for resistant ventricular tachycardia and WPW syndrome, with radiofrequency ablation.

Class two agents are beta blockers that block beta-1 receptors on the heart, lowering sympathetic activity and slowing AV nodal conduction to treat supraventricular tachycardias; esmolol, propranolol, metoprolol are examples.

Class three antiarrhythmic agents block potassium channels to prolong repolarization and action potential duration, lengthening QT interval and risking torsades de pointes, with reverse use dependence favoring prevention of tachyarrhythmias.

amiodarone is a long-acting class iii antiarrhythmic with a 3–8 week half-life, blocking sodium, potassium, calcium channels and beta receptors to provide the widest antiarrhythmic spectrum.

Explores class iii antiarrhythmics—amiodarone and dronedarone, vernakalant, bretylium, sotalol, and ibutilide—covering adverse effects, non-iodinated options, atrial fibrillation indications, and acute conversion.

Class four agents block L-type calcium channels, slow SA and AV nodal depolarization, reduce automaticity, and use verapamil or diltiazem to treat SVT and control rate in AF and flutter.

Explore class five antiarrhythmics such as digoxin and adenosine; digoxin increases vagal activity to control ventricular rate in atrial fibrillation, while adenosine treats paroxysmal supraventricular tachycardia by AV node hyperpolarization.

Identify the drug of choice for acute and chronic therapy across arrhythmias. Ibutilide converts to sinus rhythm; amiodarone is for chronic use except in torsades de pointes and digitalis-induced cases.

Understand how lipids and lipoproteins transport cholesterol and triglycerides via chylomicrons and very low density lipoprotein. Metabolize triglycerides to free fatty acids via lipoprotein lipase and hepatic lipase.

Explain how IDL converts to LDL or is taken up by the liver, and how HDL mediates reverse cholesterol transport, with roles of LDL, VLDL, and chylomicrons in lipid transport.

Learn about primary hyperlipoproteinemia types 1–5, their increasing lipoproteins (chylomicrons, VLDL, LDL), and how triglyceride and cholesterol elevations relate to atherosclerosis risk, with statins, fibrates, nicotinic acid, and fenofibrate.

Explore how dyslipidemia arises from hyperlipoproteinemia and review first-line anti dyslipidemic drugs—statins, bile acid binding resins, and intestinal cholesterol absorption inhibitors—along with second-line agents fibrates and niacin.

Statins, first-line antihyperlipidemic drugs, inhibit HMG-CoA reductase to lower hepatic cholesterol and upregulate LDL receptors, reducing LDL, triglycerides, IDL, and VLDL while raising HDL, with no effect on lipoprotein a.

Pravastatin shows minimal drug and food interactions due to non microsomal metabolism and low myopathy risk. It is liver confined and useful for type 2A/2B primary hyperlipoproteinemia.

Explore how ezetimibe inhibits the NPC1L1 transporter to reduce intestinal cholesterol absorption, raise hepatic LDL receptor synthesis, and treat type IIa and IIb hyperlipoproteinemia alone or with statins.

Understand bile acid binding resins—cholestyramine, colestipol, and colesevelam—that bind bile acids in the intestinal lumen, reduce plasma bile acids, and increase hepatic LDL receptors to lower cholesterol.

Fibric acid derivatives activate PPAR alpha to upregulate lipoprotein lipase, lowering triglycerides and raising HDL; fenofibrate is a prodrug with strong LDL reduction and uricosuric effects, used for hypertriglyceridemia.

Niacin, a vitamin B3, lowers LDL, VLDL, and triglycerides while raising HDL, and also reduces lipoprotein A and fibrinogen, benefiting those at risk of coronary artery disease.

Probucol inhibits the oxidation of low-density lipoprotein via antioxidant action, lowering low-density lipoprotein and high-density lipoprotein. A lipid from Lucknow lowers low-density lipoprotein and raises high-density lipoprotein, with diarrhea.

Newer dyslipidemia drugs include probucol, with antioxidant action inhibiting LDL oxidation and lowering LDL and HDL cholesterol, and Google lipid, which modestly lowers LDL and raises HDL, causing diarrhea.